Ustekinumab Injection

Ustekinumab Injection

Form: SQ and IV injection

Strength: SQ:: 45 mg, 90 mg; IV: 130 mg/vial

Reference Brands: Stelara(US)

Category: Immune Disorder

Ustekinumab injection, marketed as Stelara, is approved in the US by the FDA and in the EU via EMA for Crohn’s disease, psoriatic arthritis, and psoriasis. Regulatory approval requires comprehensive dossiers including clinical trial data, manufacturing details, safety, efficacy, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical and quality data, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and market entry strategies, visit PharmaTradz. Ensuring thorough regional compliance is essential for the safe, effective, and timely approval of ustekinumab injectable products worldwide, supporting optimal patient outcomes in autoimmune disease management.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Belimumab prefilled syringe

Strength: 200 mg/ten 1 mL for SQ; 10 mg/mL for IV

Form: Subcutaneous (SC) and intravenous (IV) Prefilled syringe

Reference Brands: Benlysta(US & EU)

View Details Get Enquiry
Anakinra injection

Strength: 100 mg/mL

Form: Injection(SQ)

Reference Brands: Kinerso, Kineret(US)

View Details Get Enquiry
IVIG (Intravenous Immunoglobulin) solution

Strength: 5% or 10%

Form: Intravenous infusion

Reference Brands: Gammagard (Gamunex-C, Flebogamma),Privigen, Octagam, Gamunex-C(US)

View Details Get Enquiry
Everolimus tablets

Strength: 0.75 mg, 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg

Form: Tablet

Reference Brands: Zortress, Afinitor(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.